Tetrathiomolybdate blocks bFGF- but not VEGF-induced incipient angiogenesis in vitro

Anticancer Res. 2006 May-Jun;26(3A):1753-8.

Abstract

Background: Angiogenesis is a multi-step process which involves endothelial cell sprouting from existing blood vessels, followed by migration, proliferation, alignment and tube formation. Tetrathiomolybdate (TM) is a multi-hit antiangiogenic agent with actions against multiple angiogenic pathways. These inhibitory effects of TM are attributed to its potent copper level-reducing property. Copper is needed for activation of various angiogenic pathways at the transcriptional and protein levels.

Materials and methods: The direct effects of TM on angiogenesis of endothelial cells were examined using an in vitro sprout-forming system.

Results: It was shown that depletion of copper by TM selectively repressed bFGF-induced, but not VEGF-induced sprout formation (an early angiogenic step).

Conclusion: This model permitted the separation of VEGF- and bFGF- induced early angiogenesis in vitro, and indicated the existence of mechanistic differences between bFGF- and VEGF- induced early angiogenic events.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Copper / metabolism
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Fibroblast Growth Factor 2 / antagonists & inhibitors*
  • Fibroblast Growth Factor 2 / pharmacology
  • Humans
  • Molybdenum / pharmacology*
  • Neovascularization, Physiologic / drug effects*
  • Neovascularization, Physiologic / physiology
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor A / pharmacology

Substances

  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • Copper
  • Molybdenum
  • tetrathiomolybdate